Added to YB: 2026-02-16
Pitch date: 2026-02-12
LFVN [neutral]
LifeVantage Corporation
+2.85%
current return
Author Info
No bio for this author
Company Info
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre and pro-biotics and skin and hair care products.
Market Cap
$64.4M
Pitch Price
$4.92
Price Target
N/A
Dividend
3.58%
EV/EBITDA
4.72
P/E
8.36
EV/Sales
0.31
Sector
Personal Care Products
Category
turnaround
LifeVantage ($LFVN) - Q2 2026 Review - Watchlist 02/2026
LFVN (earnings): Q2 rev $48.9M, down 27.8% YOY (vs $54.8M est) as pharma GLP-1 drugs (Ozempic) crushed MindBody system sales; active accounts fell 25%. Gross margin dropped to 74% from 80.5%. FY26 guidance cut to $185-200M from $227M. CEO retiring Apr'26. $60M buyback announced. Zero debt, $10.2M cash (halved in 6mo). Intl stable. 4-5/10 rating
Read full article (3 min)